Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BMRA NASDAQ:CTXR NASDAQ:GELS NASDAQ:NTBL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBMRABiomerica$3.60+2.9%$3.29$1.93▼$10.16$9.17M0.35283,525 shs8,553 shsCTXRCitius Pharmaceuticals$1.46+1.0%$1.17$0.65▼$26.25$15.37M1.23801,854 shs219,799 shsGELSGelteq$1.91+4.4%$1.80$0.77▼$5.50$18.04MN/A1.40 million shs63,301 shsNTBLNotable Labs$0.25$0.33$0.22▼$4.24$2.24M0.981.01 million shs2.11 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBMRABiomerica+2.94%+15.51%+10.76%+4.48%+31.54%CTXRCitius Pharmaceuticals-5.88%-13.77%+33.33%+75.59%-92.73%GELSGelteq+0.55%+3.98%+14.38%-36.46%+182,999,900.00%NTBLNotable Labs0.00%0.00%0.00%0.00%-65.57%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBMRABiomerica0.6443 of 5 stars0.05.00.00.01.10.80.0CTXRCitius Pharmaceuticals2.5793 of 5 stars3.34.00.00.01.10.81.3GELSGelteqN/AN/AN/AN/AN/AN/AN/AN/ANTBLNotable LabsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBMRABiomerica 0.00N/AN/AN/ACTXRCitius Pharmaceuticals 2.50Moderate Buy$53.003,542.61% UpsideGELSGelteq 0.00N/AN/AN/ANTBLNotable Labs 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownLatest NTBL, BMRA, GELS, and CTXR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/30/2025CTXRCitius PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.006/9/2025CTXRCitius PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.005/23/2025CTXRCitius PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold5/23/2025CTXRCitius PharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/15/2025CTXRCitius PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00(Data available from 7/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBMRABiomerica$5.68M1.61N/AN/A$3.13 per share1.15CTXRCitius PharmaceuticalsN/AN/AN/AN/A$10.25 per shareN/AGELSGelteq$100K180.37N/AN/A$1.30 per share1.47NTBLNotable Labs$313K7.14N/AN/A$6.81 per share0.04Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBMRABiomerica-$5.98M-$2.32N/A∞N/A-85.42%-85.90%-61.06%8/26/2025 (Estimated)CTXRCitius Pharmaceuticals-$39.14MN/A0.001.16N/AN/A-58.63%-37.67%8/11/2025 (Estimated)GELSGelteq-$2.33MN/A0.00∞N/AN/AN/AN/AN/ANTBLNotable Labs-$11.26MN/A0.00∞N/AN/A-80.81%-62.86%N/ALatest NTBL, BMRA, GELS, and CTXR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q3 2025CTXRCitius Pharmaceuticals-$0.76N/AN/AN/A$1.92 millionN/A5/14/2025Q2 2025CTXRCitius Pharmaceuticals-$1.08-$1.27-$0.19-$1.27N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBMRABiomericaN/AN/AN/AN/AN/ACTXRCitius PharmaceuticalsN/AN/AN/AN/AN/AGELSGelteqN/AN/AN/AN/AN/ANTBLNotable LabsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBMRABiomericaN/A3.762.76CTXRCitius PharmaceuticalsN/A0.370.06GELSGelteqN/A0.79N/ANTBLNotable Labs0.032.772.77Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBMRABiomerica22.28%CTXRCitius Pharmaceuticals16.88%GELSGelteqN/ANTBLNotable Labs70.48%Insider OwnershipCompanyInsider OwnershipBMRABiomerica15.00%CTXRCitius Pharmaceuticals10.70%GELSGelteqN/ANTBLNotable Labs1.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBMRABiomerica602.55 million2.16 millionOptionableCTXRCitius Pharmaceuticals2010.63 million9.50 millionOptionableGELSGelteqN/A9.44 millionN/AN/ANTBLNotable Labs409.02 million9.54 millionNo DataNTBL, BMRA, GELS, and CTXR HeadlinesRecent News About These CompaniesNotable Labs, Ltd. (NTBLQ)February 13, 2025 | finance.yahoo.comWhat Factors Have Led to Notable Labs Ltd (NTBL) Stock Trading -93.03% Below Its 52-Week High?October 22, 2024 | bovnews.comBNotable Labs Ltd (NTBL) Stock: Greater Than Its Current Valuation?October 18, 2024 | bovnews.comBNotable Labs files for bankruptcy, ending ambitions for Boehringer cancer drugOctober 16, 2024 | fiercebiotech.comFNotable Labs Pauses Implementation of Cancer Drug Volasertib Study, Announces LayoffsSeptember 20, 2024 | marketwatch.comNotable Labs (NTBL) was downgraded to a Hold Rating at JMP SecuritiesSeptember 20, 2024 | markets.businessinsider.comNotable Labs to Present Data on September 4th at SOHO 2024August 29, 2024 | globenewswire.comNotable Labs Announces CEO TransitionAugust 27, 2024 | finance.yahoo.comNTBL Stock Earnings: Notable Labs Misses EPS for Q2 2024August 16, 2024 | investorplace.comLA’s best burrito is a lab-engineered marvelAugust 15, 2024 | msn.comNotable Labs: Q2 Earnings SnapshotAugust 15, 2024 | sfgate.comNotable Labs, Ltd. (NTBL)July 26, 2024 | finance.yahoo.comIt’s Better to Hope for Prosperity than Become Adversary: Notable Labs Ltd (NTBL) StockJuly 25, 2024 | bovnews.comBNotable Labs Cleared by FDA to Begin Phase II Trial of Volasertib in AMLJuly 24, 2024 | precisionmedicineonline.comPNotable Labs Receives FDA Clearance to Proceed Further with Volasertib Phase 2 StudyJuly 24, 2024 | globenewswire.comNPC Labs raises $18M to bring mainstream games to Web3July 22, 2024 | venturebeat.comVBears are Losing Control Over Notable Labs (NTBL), Here's Why It's a 'Buy' NowMay 24, 2024 | zacks.comOppenheimer raised the price target for the Notable Labs Ltd (NASDAQ:NTBL) stock to “”a Perform””May 24, 2024 | bovnews.comBNTBL Stock Earnings: Notable Labs Misses EPS for Q1 2024May 16, 2024 | investorplace.comBuy Rating Affirmed for Notable Labs Amid Promising Drug Program and Robust PPMP PlatformMay 16, 2024 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNTBL, BMRA, GELS, and CTXR Company DescriptionsBiomerica NASDAQ:BMRA$3.60 +0.10 (+2.89%) As of 01:38 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.Citius Pharmaceuticals NASDAQ:CTXR$1.46 +0.02 (+1.04%) As of 01:44 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.Gelteq NASDAQ:GELS$1.91 +0.08 (+4.41%) As of 01:21 PM EasternGelteq Inc. is a biotechnology company which specializes in the formulation, development and manufacturing of ingestible gel platform designed for nutrient and drug delivery. The Company is focused on advancing and commercializing its delivery solutions within core verticals pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications and sports nutrition. Gelteq Inc. is based in NEW YORK.Notable Labs NASDAQ:NTBLNotable Labs, Ltd., a clinical-stage platform therapeutics company, develops predictive precision medicines for patients with cancer. The company, through its proprietary Predictive Precision Medicines Platform (PPMP), bio-simulates a cancer treatment and predicts, whether or not the patient will clinically respond to their actual treatment. Its PPMP is designed to identify and select clinically responsive patients prior to their treatment and enables fast-track therapeutic development in this patient population. The company's pipeline includes Volasertib, a potent Polo-like kinase 1 (PLK-1) inhibitor to induce cell cycle arrest and apoptosis in various cancer cells; and Fosciclopirox, a pro-drug of ciclopirox for acute myeloid leukemia. Notable Labs, Ltd. was incorporated in 2014 and is headquartered in Foster City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Rigetti Soars 30% on Latest Quantum Leap: What It Means Long-Term Domino’s Delivers Another Discounted Entry for Income Investors 3 Reasons Palo Alto Networks Is Becoming a Wall Street Favorite Vertical Aerospace Stock Trades at Discount After VX4 Milestone GameStop: Clarity Brings Renewed Confusion for Meme Stock Analysts Are Backing Qualcomm: Is a Breakout Coming? TSLA Earnings Week: Can Tesla Break Through $350? D-Wave Rises 12% in 1 Day, Beating Rivals: What Caused the Spike? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
